|
1
|
Ponta H, Sherman L and Herrlich PA: CD44:
From adhesion molecules to signalling regulators. Nat Rev Mol Cell
Biol. 4:33–45. 2003. View
Article : Google Scholar : PubMed/NCBI
|
|
2
|
Zöller M: CD44: Can a cancer-initiating
cell profit from an abundantly expressed molecule? Nat Rev Cancer.
11:254–267. 2011. View
Article : Google Scholar : PubMed/NCBI
|
|
3
|
Visvader JE and Lindeman GJ: Cancer stem
cells: Current status and evolving complexities. Cell Stem Cell.
10:717–728. 2012. View Article : Google Scholar : PubMed/NCBI
|
|
4
|
Günthert U, Hofmann M, Rudy W, Reber S,
Zöller M, Haussmann I, Matzku S, Wenzel A, Ponta H and Herrlich P:
A new variant of glycoprotein CD44 confers metastatic potential to
rat carcinoma cells. Cell. 65:13–24. 1991. View Article : Google Scholar : PubMed/NCBI
|
|
5
|
Friedrichs K, Franke F, Lisboa BW, Kügler
G, Gille I, Terpe HJ, Hölzel F, Maass H and Günthert U: CD44
isoforms correlate with cellular differentiation but not with
prognosis in human breast cancer. Cancer Res. 55:5424–5433.
1995.PubMed/NCBI
|
|
6
|
Seelentag WK, Günthert U, Saremaslani P,
Futo E, Pfaltz M, Heitz PU and Roth J: CD44standard and variant
isoform expression in human epidermal skin tumors is not correlated
with tumor aggressiveness but down-regulated during proliferation
and tumor de-differentiation. Int J Cancer. 69:218–224. 1996.
View Article : Google Scholar : PubMed/NCBI
|
|
7
|
Olsson E, Honeth G, Bendahl PO, Saal LH,
Gruvberger-Saal S, Ringnér M, Vallon-Christersson J, Jönsson G,
Holm K, Lövgren K, et al: CD44 isoforms are heterogeneously
expressed in breast cancer and correlate with tumor subtypes and
cancer stem cell markers. BMC Cancer. 11:4182011. View Article : Google Scholar : PubMed/NCBI
|
|
8
|
Okamoto I, Morisaki T, Sasaki J, Miyake H,
Matsumoto M, Suga M, Ando M and Saya H: Molecular detection of
cancer cells by competitive reverse transcription-polymerase chain
reaction analysis of specific CD44 variant RNAs. J Natl Cancer
Inst. 90:307–315. 1998. View Article : Google Scholar : PubMed/NCBI
|
|
9
|
Yamaguchi A, Urano T, Goi T, Saito M,
Takeuchi K, Hirose K, Nakagawara G, Shiku H and Furukawa K:
Expression of a CD44 variant containing exons 8 to 10 is a useful
independent factor for the prediction of prognosis in colorectal
cancer patients. J Clin Oncol. 14:1122–7112. 1996.PubMed/NCBI
|
|
10
|
Yamaguchi A, Saito M, Goi T, Iida A,
Takeuchi K, Hirose K, Nakagawara G, Urano T, Furukawa K and Shiku
H: Expression of CD44 variant exons 8-10 in gastric cancer. Jpn J
Cancer Res. 86:1166–1171. 1995. View Article : Google Scholar : PubMed/NCBI
|
|
11
|
Lau WM, Teng E, Chong HS, Lopez KA, Tay
AY, Salto-Tellez M, Shabbir A, So JB and Chan SL: CD44v8-10 is a
cancer-specific marker for gastric cancer stem cells. Cancer Res.
74:2630–2641. 2014. View Article : Google Scholar : PubMed/NCBI
|
|
12
|
Zeng Y, Wodzenski D, Gao D, Shiraishi T,
Terada N, Li Y, Vander Griend DJ, Luo J, Kong C, Getzenberg RH and
Kulkarni P: Stress-response protein RBM3 attenuates the stem-like
properties of prostate cancer cells by interfering with CD44
variant splicing. Cancer Res. 73:4123–4133. 2013. View Article : Google Scholar : PubMed/NCBI
|
|
13
|
Weilbaecher KN, Guise TA and McCauley LK:
Cancer to bone: A fatal attraction. Nat Rev Cancer. 11:411–425.
2011. View
Article : Google Scholar : PubMed/NCBI
|
|
14
|
Abraham BK, Fritz P, McClellan M,
Hauptvogel P, Athelogou M and Brauch H: Prevalence of
CD44+/CD24-/low cells in breast cancer may not be associated with
clinical outcome but may favor distant metastasis. Clin Cancer Res.
11:1154–1159. 2005.PubMed/NCBI
|
|
15
|
Balic M, Lin H, Young L, Hawes D, Giuliano
A, McNamara G, Datar RH and Cote RJ: Most early disseminated cancer
cells detected in bone marrow of breast cancer patients have a
putative breast cancer stem cell phenotype. Clin Cancer Res.
12:5615–5621. 2006. View Article : Google Scholar : PubMed/NCBI
|
|
16
|
Hiraga T, Ito S and Nakamura H: Cancer
stem-like cell marker CD44 promotes bone metastases by enhancing
tumorigenicity, cell motility, and hyaluronan production. Cancer
Res. 73:4112–4122. 2013. View Article : Google Scholar : PubMed/NCBI
|
|
17
|
Nakamura H, Kato R, Hirata A, Inoue M and
Yamamoto T: Localization of CD44 (hyaluronan receptor) and
hyaluronan in rat mandibular condyle. J Histochem Cytochem.
53:113–120. 2005. View Article : Google Scholar : PubMed/NCBI
|
|
18
|
Warzecha CC, Sato TK, Nabet B, Hogenesch
JB and Carstens RP: ESRP1 and ESRP2 are epithelial
cell-type-specific regulators of FGFR2 splicing. Mol Cell.
33:591–601. 2009. View Article : Google Scholar : PubMed/NCBI
|
|
19
|
Brown RL, Reinke LM, Damerow MS, Perez D,
Chodosh LA, Yang J and Cheng C: CD44 splice isoform switching in
human and mouse epithelium is essential for epithelial-mesenchymal
transition and breast cancer progression. J Clin Invest.
121:1064–1074. 2011. View
Article : Google Scholar : PubMed/NCBI
|
|
20
|
Yae T, Tsuchihashi K, Ishimoto T, Motohara
T, Yoshikawa M, Yoshida GJ, Wada T, Masuko T, Mogushi K, Tanaka H,
et al: Alternative splicing of CD44 mRNA by ESRP1 enhances lung
colonization of metastatic cancer cell. Nat Commun. 3:8832012.
View Article : Google Scholar : PubMed/NCBI
|
|
21
|
Bartolazzi A, Jackson D, Bennett K, Aruffo
A, Dickinson R, Shields J, Whittle N and Stamenkovic I: Regulation
of growth and dissemination of a human lymphoma by CD44 splice
variants. J Cell Sci. 108:1723–1733. 1995.PubMed/NCBI
|
|
22
|
Oskarsson T, Batlle E and Massagué J:
Metastatic stem cells: Sources, niches, and vital pathways. Cell
Stem Cell. 14:306–321. 2014. View Article : Google Scholar : PubMed/NCBI
|
